Platinum Industries Ltd

- For the Oleo Chemicals segment, Platinum Industries plans a Capex of around ₹150-200 crores. - Funding options for this Capex are not yet finalized; possibilities include internal accruals, debt, or equity raising depending on the situation at that time. - Currently, the company is net debt-free and maintains a healthy cash position for ongoing operations and future investments. - No specific plans for immediate fundraising through debt or equity were mentioned. - Management indicated that future fundraising mode will be decided based on the circumstances when the investment is due.

- **Oleo Chemicals Capacity:** Planned investment of ₹150-200 crores to set up a 40,000 tonnes capacity for Oleamides and derivatives, expected after initial R&D and seed marketing phase in FY 2027. - **Egypt Plant:** Construction completion expected by May 2026; commercial production to start by September 2026 (full run by December 2026). This plant adds 60,000 tonnes capacity primarily for lead-based stabilizers. - **Palghar Facility:** Additional facility of 60,000 MT each for PVC stabilizers and CPVC in Palghar is nearing optimal utilization; calcium zinc production expected to scale up fully by April 2026. - **Pharma Subsidiary (Rivadu Lifesciences Pvt Ltd):** No immediate Capex disclosed, but expects to generate revenue in FY 2027 through CDMO and contracting before possible future investment. - **Funding Strategy:** Capex to be funded via internal accruals, debt, or equity depending on the situation at the time.

Future Growth Expectations for Platinum Industries Limited: - Targeting over 40% revenue growth in FY 2027. - Expecting a 35% CAGR in revenue from FY 2026 to FY 2029. - New Egypt facility to contribute significantly, targeting ₹250-300 crores revenue in three years at around 50% utilization. - Indian operations: new plants (Unit 1 and Unit 2) expected to generate ₹700-750 crores (PVC) and ₹600 crores (CPVC) revenue over 3-4 years. - Capacity expansions at Palghar (12,000 T CPVC operational, full calcium zinc production expected by April 2026). - Growth fueled by deeper market penetration, portfolio expansion, automation, improved capacity utilization and process efficiency. - Robust structural tailwinds from India's PVC market with expected 8%+ CAGR driven by government initiatives (housing, smart cities). - Egypt plant commissioning expected by September 2026, full operation by December 2026.

- Platinum Industries targets over 40% revenue growth in FY 2027 and a 35% CAGR from FY 2026 to FY 2029. - EBITDA margin from Egypt segment is expected initially at 12%-13%, improving to 15%-16% over time. - Overall company EBITDA margins are projected around 15%-17% based on product mix. - Stable state PAT margin guidance is around 11%-12% for the entire portfolio. - Egypt operations are expected to add revenue of ₹250-300 crores over three years, with potential margin expansion due to operational efficiencies. - CPVC product margins are improving and expected to mature, contributing positively to earnings. - Capex in new segments like Oleo Chemicals (~₹150-200 crores) may be funded through internal accruals/debt/equity, supporting future growth. - Management aims for continued profit growth driven by volume expansion, operational efficiencies, and capacity utilization.

The transcript provided does not explicitly mention the current or expected order book or pending orders for Platinum Industries Limited. However, relevant points related to orders and capacity utilization include: - From January 2026, after PVC prices reversed upwards, order inflow and run rates have improved, indicating positive demand momentum. - Egypt plant capacity (60,000 tonnes) expected to be operational for about six months in FY 2027, targeting revenues of ₹250-300 crores over three years. - Palghar facility expansion nearing optimal utilization, with expectations to scale up volumes. - CPVC plant at Palghar running at 60-65% capacity currently, with full production scaling planned from April 2026. - Revenue growth guided at over 40% in FY 2027 and CAGR of 35% from FY 2026 to FY 2029, implying strong future order inflows. - Management emphasizing capacity ramp-up, market penetration, and new product launches to meet demand. No specific order book or pending orders value is directly disclosed.